The governed
smart injection device for
traceable compound
delivery.
AXIS is the AXIONOVA™ hybrid smart-manual injector. It verifies the exact-dose CDM Cartridge by NFC, applies local interlocks, refuses invalid administration, and records every event under ALETHRA™ governance.
A controlled instrument,
not an isolated injector.
AXIS keeps the human in control while the device confirms that each administration is authorized, properly staged, and recorded. There is no dose selector: the CDM Cartridge is pre-filled to the exact prescribed volume, and AXIS displays it as read-only status. It is a specialized biometric instrument utilized exclusively within physician-governed clinical environments. It is not a general consumer device and operates as part of a prescribed clinical protocol.
Verify, deliver,
and record the event.
AXIS reads the CDM Cartridge identity and signed payload, checks authorization, and refuses any unauthorized, expired, used, or mismatched cartridge before delivery. Only after verification does it deliver the full cartridge contents, then bind cartridge identity, dose-event metadata, and device state to an ALETHRA™ audit record.
Clinics, practitioners,
and authorized programs.
AXIS use is gated by role, protocol, identity, and authorization. It works as one verified system with the CDM Cartridge, gives professional teams a traceable administration record, and connects to the wider AXIONOVA™ platform. Registration is the access path for qualified facilities and licensed professionals.
Physician-Directed: AXIS separates measured and recorded device events (cartridge identity, read-only cartridge-dose metadata, device state, and refusal reasons) from derived interpretation. ALETHRA™ governs the system, ALETHA™ guides the experience, and a licensed physician authorizes every clinical outcome. All clinical decisions, diagnoses, and prescriptions are made by independent licensed physicians. AXIONOVA™ does not practice medicine.
Register for AXIS access.
Access is not open. AXIS requires registration, qualification review, and role-based authorization.